

# Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

NCT05762211

---

Status	RECRUITING
Phase	Phase 2
Sponsor	MaaT Pharma
Enrollment	387 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Age e 50 years old
  - Presence of a hematologic malignancy for which an alloHCT is indicated with a reduced toxicity or reduced intensity conditioning regimen
  - Patients with polynuclear neutrophils  $\geq 0.5$  G/L
  - Patients having received wide spectrum antibiotics within the last 90 days prior to inclusion
  - Karnofsky index e 70%
- ... and 2 more (see full listing online)

### Exclusion (21)

- Patients planned to receive a non-myeloablative conditioning regimen (2 Gray total body irradiation (TBI) +/- purine analog, fludarabine + cyclophosphamide or equivalent)
  - Patients planned to receive a conventional myeloablative conditioning regimen (e.g. high dose cyclophosphamide and high dose TBI (e10Gy); high dose busulfan (12.8 mg/kg IV) + high dose cyclophosphamide)
  - Patients receiving a manipulated graft (in-vitro T-cell depletion)
  - Patients planned to receive a conditioning regimen with alemtuzumab
  - Patients planned to receive alloHCT with cord blood cells
- ... and 16 more (see full listing online)

## Locations (54 total)

---

Universitair Ziekenhuis Antwerpen, Antwerp, Belgium  
AZ Sint - Jan Brugge, Bruges, Belgium  
Institut Jules Bordet, Brussels, Belgium  
... and 51 more locations

---

<https://clinicaltrials.gov/study/NCT05762211>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://ClinicalTrials.gov). Generated by [ClinicalTrialsFinder.org](https://ClinicalTrialsFinder.org).